Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 19;11(5):ofae139.
doi: 10.1093/ofid/ofae139. eCollection 2024 May.

Sex-Based Disparities in the Transition to Dolutegravir-Based Antiretroviral Therapy in West African HIV Cohorts

Thierry Tiendrebeogo  1 , Karen Malateste  1 , Armel Poda  2 , Albert Minga  3 , Eugene Messou  4   5   6 , Henri Chenal  7 , Oliver Ezechi  8 , Didier K Ekouevi  1   9 , Igho Ofotokun  10 , Antoine Jaquet  1 ; IeDEA West Africa Collaboration
Collaborators, Affiliations

Sex-Based Disparities in the Transition to Dolutegravir-Based Antiretroviral Therapy in West African HIV Cohorts

Thierry Tiendrebeogo et al. Open Forum Infect Dis. .

Abstract

Transition to dolutegravir among 21 167 individuals experienced in antiretroviral therapy in West Africa showed heterogeneous timelines and patterns. Initially reported sex disparities tended to catch up over time with persisting disparities, according to contributing HIV clinics. Key factors facilitating dolutegravir switch were male sex, age <50 years, viral suppression, and regimens not based on protease inhibitors.

Keywords: HIV; West Africa; dolutegravir; sex disparities; switch.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Cumulative incidence function of the switch to dolutegravir (DTG) by sex according to participating cohorts and countries. IeDEA West Africa Collaboration, 2019–2021. CEPREF, Centre de Prise en charge de Recherche et de Formation; CHUSS, Souro Sanou University Hospital Center; CIRBA, Integrated Centre for Bioclinical Research; CMSDS, Centre medical de Suivi des Donneurs de Sang; NIMR, National Institute of Medical Research.
See this image and copyright information in PMC

References

    1. Deutschmann E, Bucher HC, Jaeckel S, et al. Prevalence of potential drug-drug interactions in patients of the Swiss HIV Cohort Study in the era of HIV integrase inhibitors. Clin Infect Dis 2021; 73:e2145–52. - PubMed
    1. Fantauzzi A, Mezzaroma I. Dolutegravir: clinical efficacy and role in HIV therapy. Ther Adv Chronic Dis 2014; 5:164–77. - PMC - PubMed
    1. Kanters S, Vitoria M, Doherty M, et al. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. Lancet HIV 2016; 3(11):e510–20. - PubMed
    1. Molina JM, Clotet B, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV 2015; 2(4):e127–36. - PubMed
    1. World Health Organization . Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines. Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. 2018. Available at: https://www.who.int/publications/i/item/WHO-CDS-HIV-18.51. Accessed 16 October 2023.